Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Submission date	Recruitment status	 Prospectively registered
14/08/2024	Recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
03/09/2024	Deferred	☐ Results
Last Edited	Condition category	Individual participant data
16/05/2025	Other	[X] Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal Investigator

Contact name

Prof Kyriakos Lobotesis

ORCID ID

http://orcid.org/0000-0001-5093-9751

Contact details

Imperial College Healthcare NHS Trust Charing Cross Hospital Fulham Palace Road London United Kingdom W6 8RF

k.lobotesis@nhs.net

Type(s)

Public, Scientific

Contact name

Dr Philip Pratt

Contact details

Medical iSight (UK) Ltd 9th Floor 107 Cheapside London United Kingdom EC2V 6DN

_

pjp@medicalisight.com

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

319189

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CPMS 54208

Study information

Scientific Title

Multimodal Augmented Reality for Operative Guidance in Interventional Neuroradiology

Acronym

MAROG-INR

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 21/02/2023, London - Dulwich Research Ethics Committee (Skipton House, 80 London Road, London, SE1 6LH, United Kingdom; +44 (0)207 104 8290; dulwich.rec@hra.nhs.uk), ref: 23 /LO/0030

Study design

Single-centre interventional trial in patients undergoing interventional neuroradiology procedures

Primary study design

Interventional

Secondary study design

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Other

Primary outcome measure

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Secondary outcome measures

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Overall study start date

29/11/2022

Completion date

01/07/2026

Eligibility

Key inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

50

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

01/09/2024

Date of final enrolment

01/04/2026

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Charing Cross Hospital

Fulham Palace Road London United Kingdom W6 8RF

Sponsor information

Organisation

Medical iSight (UK) Limited

Sponsor details

9th Floor 107 Cheapside London England United Kingdom EC2V 6DN

_

pjp@medicalisight.com

Sponsor type

Industry

Website

https://www.medicalisight.com/

Funder(s)

Funder type

Other

Funder Name

Self-funded

Results and Publications

Publication and dissemination plan

Full trial details will be published up to 30 months after the end of the trial. Results will be posted on or after the date of publication of full trial details.

Intention to publish date

21/02/2026

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available